A long-standing issue concerns the extent to which fragile sites predispose to cancer-associated chromosomal rearrangements. The FHIT gene at chromosome 3p14.2 spans the most common fragile site, FRA3B, in the human genome. Although the FHIT gene is altered in many human cancers, its status as a tumor suppressor gene has remained controversial, particularly since functional studies provided contradictory results. It had been suggested the FHIT alterations result from FRA3B induction promoted by the interference of carcinogens with DNA replication. Here we investigated the eect of FRA3B induction on FHIT expression. Common fragile sites were induced by treatment with aphidicolin and scored cytogenetically. FHIT transcription was analysed by RT ± PCR and RNase protection analysis. Unexpectedly, FHIT transcription proceeded unchanged after fragile site induction. Aberrant FHIT transcripts lacking one or more exons were not observed. Morevover, Western blots revealed that the levels of FHIT prior to and following fragile site induction was unchanged, whereas p53 was found at elevated levels after induction. FRA3B induction thus has no direct eect on FHIT transcription and translation. Oncogene (2001) 20, 1798 ± 1801.
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Examination of the relationships between DNA damage and mutagenesis provides insights into the molecular mechanisms underlying cancer development. The identi®cation and characterization of genomic regions that preferentially undergo DNA damageinduced rearrangements are important issues. In this respect, a long-standing question concerns the extent to which fragile sites predispose to cancer-associated chromosomal rearrangements (Le Beau and Rowley, 1984; Yunis and Soreng, 1984) . Common fragile sites are speci®c regions that appear as gaps and breaks in metaphase chromosomes when DNA replication is perturbed (for review, see Sutherland et al., 1998) . Interest in fragile sites has been further stimulated by cloning of the fragile histidine triad (FHIT) gene which spans the most common fragile site in the human genome, FRA3B, at chromosome 3p14.2. This region shows loss of heterozygosity (LOH) in a variety of cancers. Although the FHIT gene is altered in many human cancers Sozzi et al., 1996) its status as a tumor suppressor gene has remained controversial, particularly since functional studies provided contradictory results (Siprashvili et al., 1997; Otterson et al., 1998; Ji et al., 1999; Wu et al., 2000) . Moreover the signi®cance of the FHIT gene in carcinogenesis has been questioned since Fhit null mice (Fhit 7/7) were reported to be long-lived and fertile (Fong et al., 2000) .
It has previously been proposed that FHIT alterations found in tumors result from the induction of FRA3B, possibly promoted by the interference of carcinogens with DNA replication (Sozzi et al., 1996; Fong et al., 2000) . To examine this potential mechanism of mutagenesis, we have investigated the eect of fragile site induction on FHIT expression. Common fragile sites were induced by treatment of PHA-stimulated lymphocytes with aphidicolin (Le Beau et al., 1998) , a speci®c inhibitor of DNA polymerases a, d and e. Heparinized blood samples were obtained from eight healthy donors, and three types of PHA-stimulated cultures were studied: untreated control cultures, cultures treated with aphidicolin at a ®nal concentration of 0.2 mM, and cultures treated with aphidicolin at a ®nal concentration of 0.4 mM. Controls using primary non-cultured normal peripheral blood lymphocytes from each donor were included. PHA-stimulated lymphocytes are most commonly used in studies of fragile sites, and in addition to aphidicolin various mutagens and carcinogens have been shown to induce chromosomal breaks at fragile sites in this experimental system (Yunis and Soreng, 1987) . To ascertain the induction of fragile sites by exposure to aphidicolin, GTG-banded chromosome preparations were analysed by standard cytogenetic techniques (Barch, 1991) (data not shown).
Initially FHIT transcription was analysed prior to and following fragile site induction. Transcripts com-prising the entire open reading frame were ampli®ed by RT ± PCR using primers corresponding to positions 261 (exon 4) and 1080 (exon 10) of the human FHIT cDNA sequence ; GenBank accession number U46922). To avoid artefacts during nested ampli®ca-tion, a robust single-stage RT ± PCR ampli®cation protocol was applied (Thiagalingam et al., 1996) . Upon treatment with aphidicolin (0.2 and 0.4 mM) only the normal-sized 820 nt FHIT transcript was detected in the samples from all eight donors (Figure 1a) . This transcript was shown to be identical to the FHIT wildtype transcript by sequence analysis (data not shown). Aberrant FHIT transcripts lacking one or several exons were not observed. Since aberrant transcripts lacking exons 3 or 4 have been reported Sozzi et al., 1996) a primer for exon 1 (position 140 of the FHIT cDNA) was used in combination with the exon 10 primer to amplify nearly the entire FHIT mRNA. However, again only the expected normal-sized 941 nt FHIT transcript was detected.
Although RT ± PCR is a sensitive method, minor eects, e.g. on the rate of transcription, may have gone undetected due to the semiquantitative nature of standard PCR assays. Therefore quantitative ribonuclease (RNase) protection analysis was performed as described (Gilman, 1993) , using an antisense probe covering the FHIT mRNA from nt 148 to nt 833. As shown in Figure 1b , FHIT mRNA levels were almost unaected by treatment with aphidicolin (lanes 3 ± 6). Control experiments using increasing amounts of mRNA showed that the intensity of the protected bands correlated with amounts of mRNA, con®rming that the antisense probe was in high molar excess (data not shown).
It has been reported that FHIT translation may be repressed despite ecient transcription (Huebner et al., 1998) . Therefore FHIT translation was analysed as well. Consistent with the results of RT ± PCR and RNase protection experiments, Western blots revealed the same high level of FHIT protein prior to and following fragile site induction (Figure 2, upper panel) . Thus, neither FHIT transcription nor translation were signi®cantly altered by the induction of fragile sites.
Upon their induction, fragile sites are hot spots for sister chromatid exchange (SCE) (Glover and Stein, 1987; Wenger et al., 1987) . As a key step SCE involves the generation of DNA double-strand breaks, i.e., a type of DNA lesion capable of triggering p53- Figure 1 Fragile site induction does not interfere with FHIT transcription. (a) Southern blot analysis of the RT ± PCR products from RNA of normal lymphocytes (1) and PHA-stimulated lymphocytes, either untreated (2) or exposed to aphidicolin at concentrations of 0.2 mM (3) or 0.4 mM (4). For hybridization a FHIT-speci®c 32 P-labeled cDNA probe comprising nt 261 to 1080 was used. Lanes marked + and 7 correspond to RT-reactions with and without reverse transcriptase. Migration of molecular weight markers is indicated in bp on the left margin. (b) RNase protection assay from mRNA of normal lymphocytes (3) and PHAstimulated lymphocytes, either untreated (4) or exposed to aphidicolin at concentrations of 0.2 mM (5) or 0.4 mM (6). Four mg of poly(A) + were bybridized with 5610 5 c.p.m. of gel puri®ed 32 P-labelled antisense probe in 30 ml formamide buer. After RNase A/ RNase T1 and subsequent proteinase K digestion, the samples were phenol-extracted and loaded onto a 6% sequencing gel. Lanes marked (1) and (2) show the undigested probe (1) and a control reaction with yeast tRNA (2). The fragment size of the pBluescript HpaII molecular weight marker is indicated in bp on the left margin and, therefore, does not precisely re¯ect the size of the unprotected and protected RNA fragments dependent DNA damage response pathways (Nelson and Kastan, 1994; Huang et al., 1996) . We therefore investigated whether the p53 pathway was activated in the experimental system used here. Since the amount and the activity of p53 are mainly regulated posttranslationally, p53 was examined by Western blot analysis (Figure 2, central panel) . Whereas in normal lymphocytes p53 was hardly detectable (lane 1), p53 accumulation was readily detected in PHA-stimulated lymphocytes (lane 2). This is in agreement with previous results demonstrating upregulation of p53 after triggering resting cells into proliferation (Mosner and Deppert, 1994; Mummenbrauer et al., 1996) . p53 further accumulated upon exposure to 0.2 mM aphidicolin, and an even higher level was reached upon exposure to 0.4 mM aphidicolin (lanes 3 and 4) , indicating DNA damage-induced p53 activity.
In summary, the present analyses demonstrate that FRA3B induction has no direct eect on FHIT transcription and translation. Since the FRA3B region is late replicating, and exposure to aphidicolin further delays replication, thus resulting in incompletely replicated DNA (Le Beau et al., 1998; Wang et al., 1999) , FHIT transcription may be completed before the start of replication. Alternatively, the present results could be explained by an intact p53 pathway and/or repair of DNA double-strand breaks by homologous recombination. The alterations of the FHIT gene frequently observed in tumors are thus more likely to occur in cancer cells harboring p53 mutations and/or defects in recombinational repair. Interestingly, a correlation between FHIT deletions in tumors and their p53 mutation status has been reported (Boldog et al., 1997 
